No Data
No Data
INmune Bio Reports Promising Phase I/II Trial Results
Express News | Pmgc Holdings Inc - Co and INmune Bio Terminate License Agreement
Why INmune Bio, Inc. (INMB) Is Skyrocketing So Far in 2025
INmune Bio, Inc. (NASDAQ:INMB) Most Popular Amongst Individual Investors Who Own 36% of the Shares, Institutions Hold 28%
Maxim Group Maintains INmune Bio(INMB.US) With Buy Rating, Raises Target Price to $30
Inmune Bio Shares Are Trading Higher After the Company Announced the Completion of the Third and Highest Dose Cohort of Its Phase 1 Portion of the INKmune Trial in Prostate Cancer.